Andrew Einhorn

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Oceana Therapeutics, Inc. manufactures pharmaceuticals and medical devices. It develops and commercializes therapeutics with a focus on colorectal, gastroenterology, and urological diseases. The firm provides Deflux that is used for the treatment of Vesicoureteral reflux, urological conditions and Solesta which is used for the treatment of fecal incontinence. The company was founded in 2008 and is headquartered in Edison, NJ.

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

Oceana Therapeutics, Inc. manufactures pharmaceuticals and medical devices. It develops and commercializes therapeutics with a focus on colorectal, gastroenterology, and urological diseases. The firm provides Deflux that is used for the treatment of Vesicoureteral reflux, urological conditions and Solesta which is used for the treatment of fecal incontinence. The company was founded in 2008 and is headquartered in Edison, NJ.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Part of Rue la Boétie SAS, Credit Lyonnais provides commercial banking services. The private company is based in Frankfurt am Main, Germany.

Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel.

Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

Part of Rue la Boétie SAS, Credit Lyonnais provides commercial banking services. The private company is based in Frankfurt am Main, Germany.

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

Oceana Therapeutics, Inc. manufactures pharmaceuticals and medical devices. It develops and commercializes therapeutics with a focus on colorectal, gastroenterology, and urological diseases. The firm provides Deflux that is used for the treatment of Vesicoureteral reflux, urological conditions and Solesta which is used for the treatment of fecal incontinence. The company was founded in 2008 and is headquartered in Edison, NJ.

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.

Oceana Therapeutics, Inc. manufactures pharmaceuticals and medical devices. It develops and commercializes therapeutics with a focus on colorectal, gastroenterology, and urological diseases. The firm provides Deflux that is used for the treatment of Vesicoureteral reflux, urological conditions and Solesta which is used for the treatment of fecal incontinence. The company was founded in 2008 and is headquartered in Edison, NJ.

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

Edge Therapeutics, Inc. is clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological and other conditions. Its product candidate is the EG-1962. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ.